These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28656798)

  • 21. [Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?].
    Kanorskiy SG; Borisenko YV
    Kardiologiia; 2018 Jun; 58(6):85-89. PubMed ID: 30362441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
    Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
    [No Abstract]   [Full Text] [Related]  

  • 23. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
    Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Implications of Mitral Valve Inflow Pattern Overlap during Ivabradine Therapy.
    Imamura T; Hori M; Narang N; Besser S; Kinugawa K
    Int Heart J; 2022; 63(1):43-48. PubMed ID: 35095075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing heart rate with ivabradine in heart failure with reduced ejection fraction: Insights from a post-hoc analysis of the SHIFT trial.
    Joury A
    Eur J Heart Fail; 2023 Aug; 25(8):1436-1438. PubMed ID: 37370184
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device.
    Jedlickova L; Merkovska L; Jackova L; Janicko M; Fedacko J; Novakova B; Chmelarova A; Majernik J; Pella D
    Adv Ther; 2015 Oct; 32(10):962-70. PubMed ID: 26525390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
    Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis.
    Hartmann C; Bosch NL; de Aragão Miguita L; Tierie E; Zytinski L; Baena CP
    Int J Clin Pharm; 2018 Dec; 40(6):1443-1453. PubMed ID: 30173307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Badar AA; Perez-Moreno AC; Jhund PS; Wong CM; Hawkins NM; Cleland JG; van Veldhuisen DJ; Wikstrand J; Kjekshus J; Wedel H; Watkins S; Gardner RS; Petrie MC; McMurray JJ
    Eur Heart J; 2014 Dec; 35(48):3426-33. PubMed ID: 25265976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.
    Reil JC; Tardif JC; Ford I; Lloyd SM; O'Meara E; Komajda M; Borer JS; Tavazzi L; Swedberg K; Böhm M
    J Am Coll Cardiol; 2013 Nov; 62(21):1977-1985. PubMed ID: 23933545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ivabradine and atrial fibrillation: what should we tell our patients?
    Cowie MR
    Heart; 2014 Oct; 100(19):1487-8. PubMed ID: 24986893
    [No Abstract]   [Full Text] [Related]  

  • 35. Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy.
    Tendera M; Chassany O; Ferrari R; Ford I; Steg PG; Tardif JC; Fox K;
    Circ Cardiovasc Qual Outcomes; 2016 Jan; 9(1):31-8. PubMed ID: 26696613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction.
    Pay L; Yumurtaş AÇ; Tezen O; Çetin T; Keskin K; Eren S; Çinier G; Hayıroğlu Mİ; Çınar T; Tekkeşin Aİ
    Rev Assoc Med Bras (1992); 2023; 69(12):e20230703. PubMed ID: 37971125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ivabradine: a new frontier in the treatment of stable coronary artery disease and chronic heart failure.
    Gammone MA; Riccioni G; D'Orazio N
    Clin Ter; 2020; 171(5):e449-e453. PubMed ID: 32901791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
    Böhm M; Komajda M; Borer JS; Ford I; Maack C; Tavazzi L; Moyne A; Swedberg K;
    Eur J Heart Fail; 2018 Feb; 20(2):373-381. PubMed ID: 29027329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
    Zhu H; Xu X; Fang X; Zheng J; Zhao Q; Chen T; Huang J
    Clin Ther; 2019 Oct; 41(10):2137-2152.e12. PubMed ID: 31548105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ivabradine in stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.